Reference

Growth hormone release by gamma-aminobutyric acid (GABA) and gamma-amino-

Growth hormone release by gamma-aminobutyric acid (GABA) and gamma-amino-.beta.-hydroxybutyric acid (GABOB) in the rat. Abe, Hiromi; Kato, Yuzuru; Chihara, Kazuo; Ohgo, Shozo; Iwasaki, Yoshiko; Imura, Hiroo (Sch. Med., Kobe Univ., Kobe, Japan). Endocrinol. Jpn., 24(2), 229-31 (English) 1977. CODEN: ECJPAE. DOCUMENT TYPE: Journal CA Section: 2 (Hormone Pharmacology) Effects of GABA [56-12-2] and .gamma.-amino-.beta.-hydroxybutyric acid (GABOB) [352-21-6] on growth hormone (GH) [9002-72-6] release were investigated in the urethane-anesthetized male rat. An intraventricular injection of GABA and L-GABOB but not D-GABOB caused an increase in plasma GH. An i.v. injection of L-GABOB, at dose a which had no effect on basal plasma GH, remarkably enhanced plasma GH response to pentobarbital [57-33-0]. Apparently, GABA and L-GABOB stimulate GH release via the central nervous system in the rat.

Comparison of dose/conductance curves for GABA and some structurally related compounds at the lobster inhibitory neuromuscular junction

Comparison of dose/conductance curves for GABA and some structurally related compounds at the lobster inhibitory neuromuscular junction. Constanti, A. (Dep. Pharmacol., St. Bartholomew's Hosp., London, Engl.). Neuropharmacology, 16(5), 367-74 (English) 1977. CODEN: NEPHBW. DOCUMENT TYPE: Journal CA Section: 2 (Hormone Pharmacology) .gamma.-Amino-.beta.-hydroxybutyric acid (I) [352-21-6] (50.mu.M-3.2mM) and .delta.-aminovaleric acid (II) [660-88-8] (200.mu.M-10mM) log-dose/conductance curves at the lobster, Homarus vulgaris, inhibitory neuromuscular junction, paralleled those of GABA [56-12-2], and could be explained by the 2 independent binding site receptor model, (dissocn. const., K, 275 and 945.mu.M for I and II resp.). Guanidoacetic acid (III) [352-97-6] curves were not parallel to, and had different max. to, the GABA curves, and was fitted by a modified 2 binding site model with K1 7.4.mu.M and K2 92.mu.M. GABA, I, and II may be agonists of comparable intrinsic activity, but differing receptor affinities, whereas III may be only a partial agonist.